|
Ark Therapeutics Group Plc - Company Profile Snapshot
| Company Profile: |
Ark Therapeutics Group Plc |
| Ticker: |
AKT |
| Exchanges: |
LON |
| 2008 Sales: |
929,000 |
| Major Industry: |
Drugs, Cosmetics & Health Care |
| Sub Industry: |
Ethical Drug Manufacturers |
| Country: |
UNITED KINGDOM |
| Employees: |
155 |
Business Description
Ark Therapeutics Group Plc. The Group's principal activity is discovering, developing and commercialising products in areas of specialist medicine with particular focus on vascular disease and cancer. Its pharmaceutical business focuses on gene-based medicine that harnesses healthy brain cells to destroy cancer cells that attempt to proliferate. It is used for the treatment of patients with operable high-grade glioma, where the average survival period for patients, once diagnosed, is about eight months. It also has products designed to prevent the blocking of veins after vascular surgery. Product brands are Cerepro, Vitor and Trinam. In addition, the Group also has wound care portfolio centered on the prevention and treatment of foot, lower-leg and infected wounds. Its product brands include Kerrabot, Kerraped, Neuropad and Flaminal. The Group operates in the United Kingdom and Finland.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
